Last updated: August 15, 2026
Pemoline is a discontinued central nervous system stimulant formerly used to treat attention-deficit/hyperactivity disorder. Its commercial trajectory ended after regulators and manufacturers identified severe, sometimes fatal, liver toxicity. In the United States, Abbott Laboratories withdrew Cylert, the leading branded pemoline product, in 2005. Pemoline has no meaningful current U.S. market, no active Orange Book position of commercial significance, no biosimilar pathway, and no visible late-stage pharmaceutical investment thesis.
What is pemoline and how was it used?
Pemoline is a synthetic stimulant marketed primarily for ADHD. The U.S. brand was Cylert, manufactured by Abbott Laboratories. Products were supplied in tablet and chewable tablet forms, generally at 18.75 mg, 37.5 mg, and 75 mg strengths. Pemoline was less widely used than methylphenidate and amphetamine products but occupied a niche in the ADHD stimulant market.
The drug had a differentiated pharmacologic profile. It was classified as a central nervous system stimulant but was not structurally related to amphetamine. Its lower perceived abuse potential initially supported clinical use, although its safety profile ultimately outweighed that commercial distinction.
The principal market failure was hepatotoxicity. Reported cases included severe liver injury, liver failure, liver transplantation, and death. The risk was considered difficult to manage through routine monitoring because liver injury could occur without a reliable early warning pattern. The FDA label required liver-function monitoring and carried prominent warnings before U.S. withdrawal.[1]
When did pemoline lose exclusivity and commercial momentum?
Pemoline’s commercial decline preceded its 2005 withdrawal. The product had already lost the commercial advantages associated with originator exclusivity, and generic competition existed in the U.S. market before the branded product was withdrawn.
Pemoline commercialization timeline
| Year |
Event |
Commercial effect |
| 1975 |
FDA approved Cylert for ADHD |
Entry into the U.S. stimulant market |
| 1980s-1990s |
Expanded clinical use and generic availability |
Increasing price and market-share pressure |
| 1996 |
FDA strengthened liver-toxicity warnings and monitoring requirements |
Reduced prescribing confidence |
| 1999 |
FDA issued a public health advisory concerning hepatic failure risk |
Accelerated substitution toward other ADHD therapies |
| 2005 |
Abbott withdrew Cylert from the U.S. market |
Branded U.S. commercial business ended |
| After 2005 |
No meaningful U.S. re-commercialization |
Market became clinically and commercially inactive |
The original compound and product patents were not the principal barrier by the time of withdrawal. The relevant commercial constraint was safety, not remaining patent life. Historical patent and Orange Book records do not support a current, enforceable U.S. exclusivity position for pemoline.
What is the FDA and Orange Book status of pemoline?
Pemoline is not an active U.S. commercial product. The FDA has not approved a current pemoline product for routine U.S. marketing following withdrawal of Cylert.
The FDA’s withdrawal action was based on the risk of liver failure, not on a conventional patent or manufacturing dispute. The agency stated that continued use was not justified by the drug’s benefits when safer ADHD treatments were available.[2]
Regulatory status
| Regulatory issue |
Status |
| U.S. approved brand |
Cylert, withdrawn |
| Active U.S. marketing |
No meaningful current marketing |
| FDA approval status |
No current commercially active pemoline product |
| Orange Book relevance |
No current commercially important listed product or exclusivity position |
| Controlled-substance status |
Historically regulated as a stimulant; current legal treatment depends on jurisdiction |
| Pediatric use |
Formerly used for ADHD; no current U.S. standard-of-care role |
| Biosimilar status |
Not applicable |
| Generic status |
Historical generic availability; no meaningful current U.S. market |
A withdrawal for safety reasons does not automatically erase historical approval records or every historical patent listing. It does, however, remove the commercial value of ordinary Hatch-Waxman exclusivity unless a sponsor successfully obtains a new approval.
What patents protected pemoline?
Pemoline’s historical patent position centered on the active compound and pharmaceutical formulations. Those rights are expired or commercially irrelevant. No current patent estate appears to protect pemoline as a viable U.S. pharmaceutical franchise.
Patent categories historically relevant to pemoline
- Compound patents covering pemoline or related oxazolidinedione chemistry.
- Formulation patents covering tablets, chewable tablets, dosage strengths, or excipient systems.
- Manufacturing patents covering synthesis and crystallization.
- Method-of-use patents covering treatment of ADHD or related disorders.
Any ordinary composition-of-matter protection for a product first marketed in the 1970s would have expired decades ago under modern patent-term rules. Historical formulation and method-of-use patents would also be expected to have expired before or around the time of commercial withdrawal.
No current formulation patent, method-of-use patent, or manufacturing patent has evident value comparable to an active branded-drug estate. A new sponsor could seek patents for a redesigned formulation, delivery system, or treatment method, but those rights would protect the new product configuration rather than restore exclusivity over legacy pemoline.
Were there Paragraph IV challenges or pemoline patent litigation?
There is no material current Paragraph IV dispute affecting pemoline. The product’s commercial history does not show a current patent litigation battle involving an active reference-listed drug, a branded originator, and an abbreviated new drug application seeking market entry.
Historical generic competition was commercially more important than patent litigation. By the time of the 2005 withdrawal, the central issue was whether physicians and patients would accept pemoline’s liver risk, not whether a generic manufacturer could enter after defeating a patent.
Litigation and settlement assessment
| Issue |
Assessment |
| Current Paragraph IV challenge |
No material active dispute identified |
| Current patent-infringement litigation |
No material active dispute identified |
| Brand-generic settlement |
No commercially significant current settlement affecting entry |
| Antitrust exposure |
Low relative to active blockbuster products |
| Litigation-driven launch delay |
Not a current market factor |
| Regulatory withdrawal litigation |
Not the primary commercial driver |
How strong is the pemoline patent estate?
The current pemoline patent estate is weak from a commercial perspective. Its age, safety history, and absence of an active reference product eliminate most of the value normally associated with pharmaceutical patents.
Patent-strength assessment
| Factor |
Assessment |
| Remaining core compound protection |
None of practical commercial significance |
| Formulation protection |
Historical and likely expired |
| Method-of-use protection |
Historical and likely expired |
| Manufacturing protection |
Potentially relevant only to a newly developed process |
| Freedom to operate |
Likely manageable for legacy pemoline, subject to jurisdiction-specific review |
| Regulatory exclusivity |
None of practical current significance |
| Litigation leverage |
Minimal |
| Licensing leverage |
Minimal unless tied to a new formulation or reapproval program |
A new pemoline product would face more substantial regulatory and clinical barriers than intellectual-property barriers. The sponsor would need to address known hepatotoxicity, demonstrate a favorable benefit-risk profile, and establish a credible monitoring strategy.
What drove pemoline’s market decline?
Safety risk drove the decline more than price competition. Pemoline competed against methylphenidate, mixed amphetamine salts, dextroamphetamine, atomoxetine, and later nonstimulant ADHD therapies. These alternatives had stronger physician familiarity, broader commercial support, and more acceptable safety profiles.
Competitive comparison
| Product class |
Relative position versus pemoline |
| Methylphenidate |
Stronger market acceptance and established generic supply |
| Amphetamine products |
Higher commercial scale and extensive clinical use |
| Atomoxetine |
Nonstimulant alternative with a different safety and abuse profile |
| Guanfacine and clonidine |
Nonstimulant options, particularly relevant in pediatric treatment |
| Pemoline |
Lower abuse concern historically, but unacceptable liver-toxicity risk |
Pemoline’s reduced abuse potential did not compensate for the possibility of irreversible liver injury. Once regulators strengthened warnings and safer alternatives became widely available, switching costs were low.
What was pemoline’s financial trajectory?
No reliable public source provides a standalone, current pemoline revenue series. Abbott reported corporate and product-group results rather than a detailed, auditable Cylert revenue line. The available evidence supports a mature-product decline followed by a complete U.S. revenue collapse after withdrawal.
Financial trajectory by phase
Launch and adoption
Pemoline entered a growing ADHD market and benefited from demand for stimulant treatment. Its commercial differentiation came from its pharmacology and lower perceived abuse potential.
Mature-product period
The product faced generic competition and increasing scrutiny of liver toxicity. Prescribing restrictions, liver-function monitoring, and physician substitution reduced demand. The product became a declining niche asset rather than a growth franchise.
Withdrawal period
Abbott’s 2005 withdrawal eliminated U.S. branded revenue from Cylert. Generic revenue also became commercially insignificant because the safety concern applied to the active ingredient, not only to Abbott’s formulation.
Post-withdrawal period
There is no credible basis for assigning material current U.S. revenue to pemoline. Any residual international sales would not represent a meaningful global pharmaceutical market without evidence of active regulatory approval, distribution, and payer access.
Financial indicators
| Indicator |
Assessment |
| Current U.S. revenue |
Effectively zero |
| Current branded revenue |
No meaningful revenue base |
| Historical peak revenue |
Not reliably disclosed in public company reporting |
| Pricing power |
Lost through generic competition and safety concerns |
| Reimbursement outlook |
Weak without a new approval and differentiated clinical benefit |
| Commercial growth |
None under the legacy product |
| M&A value |
Low for the legacy molecule |
| Repositioning value |
Speculative and dependent on new clinical evidence |
What generic-entry risks exist for pemoline?
Legacy generic entry is not the principal risk because the product has already lost its commercial market. The relevant risk for a future sponsor would be regulatory and clinical failure, followed by competition from established ADHD therapies.
A sponsor seeking to revive pemoline could attempt to create market protection through:
- A controlled-release formulation.
- A lower-exposure dosing regimen.
- A targeted patient population.
- A combination product.
- A liver-monitoring or pharmacogenomic strategy.
- A new delivery system.
These approaches would face patentability and obviousness challenges. They would also need clinical evidence showing that the redesigned product materially improves the known hepatic risk. A new formulation patent alone would not solve the underlying regulatory problem.
What manufacturing and geographic barriers affect pemoline?
Pemoline synthesis is not expected to create a major technical manufacturing barrier compared with complex biologics, sterile injectables, or high-potency oncology products. The main barriers are regulatory, quality, clinical, and commercial.
Geographic commercialization would depend on local withdrawal histories and current national approvals. A product cannot rely on U.S. historical approval to support sales in other jurisdictions. Each market would require confirmation of active authorization, pharmacovigilance obligations, labeling, controlled-substance rules, and reimbursement.
No meaningful global licensing or co-development transaction currently supports pemoline. The absence of a visible licensing market is consistent with the drug’s safety profile and lack of commercial demand.
What is the outlook for a pemoline relaunch?
A conventional generic relaunch has little economic rationale. A branded relaunch would require a new benefit-risk case, substantial clinical investment, and a differentiated product protected by new intellectual property.
Relaunch scenarios
| Scenario |
Probability profile |
Commercial implication |
| Legacy generic re-entry |
Low-value |
Limited demand and weak pricing |
| New controlled-release formulation |
High development risk |
Potential protection, but safety remains unresolved |
| Narrow indication |
Possible but difficult |
Small addressable market |
| Combination product |
Limited precedent |
Requires evidence of incremental benefit |
| Full U.S. reapproval |
Low commercial attractiveness |
Large regulatory burden |
| No relaunch |
Most economically rational |
Legacy asset remains inactive |
The addressable market for ADHD treatment is large, but that does not translate into a viable pemoline opportunity. Physicians have multiple generic and branded alternatives. A pemoline sponsor would need to overcome a well-known organ-toxicity signal while competing against inexpensive, established medicines.
Key Takeaways
- Pemoline’s U.S. commercial history ended with Abbott’s 2005 withdrawal of Cylert.
- Hepatotoxicity, including liver failure and death, was the decisive market failure.
- Core compound, formulation, method-of-use, and ordinary manufacturing patents have no meaningful current exclusivity value.
- No material current Paragraph IV challenge, patent litigation, or settlement controls the market.
- Pemoline has no meaningful current U.S. revenue base.
- Biosimilar analysis does not apply because pemoline is a small-molecule drug.
- A generic relaunch would face weak demand and limited pricing power.
- A branded relaunch would require new clinical evidence, new intellectual property, and a substantially improved safety proposition.
- The principal barriers are regulatory and clinical, not manufacturing or patent-based.
- The commercial outlook for legacy pemoline is inactive; any investment case depends on a materially redesigned product.
FAQs
Is pemoline still prescribed for ADHD?
Pemoline is not part of routine U.S. ADHD treatment. Its former use was displaced by methylphenidate, amphetamine products, atomoxetine, guanfacine, clonidine, and other therapies.
Did Abbott withdraw pemoline because of patent expiration?
No. Patent erosion contributed to the mature-product economics, but the decisive event was safety. Abbott withdrew Cylert after concerns about severe hepatic injury and liver failure.
Can a company obtain new patents on pemoline?
A company may pursue patents covering a new formulation, delivery system, manufacturing process, or treatment method. It cannot obtain a new broad patent merely because the legacy compound is commercially abandoned.
Is pemoline a viable generic-drug investment?
The legacy molecule has weak generic investment characteristics. Demand is limited, safety concerns affect the entire active ingredient, and competing ADHD products are widely available.
Does pemoline have biosimilar competition?
No. Pemoline is a conventional small-molecule drug. Any competition would arise through generic or reformulated products, not biosimilars.
References
- U.S. Food and Drug Administration. (2005). FDA announces withdrawal of pemoline products.
- U.S. Food and Drug Administration. (1999). FDA public health advisory: Risk of liver failure associated with pemoline.
- U.S. Food and Drug Administration. (2005). Cylert (pemoline) product information and withdrawal materials.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- National Library of Medicine. (2024). LiverTox: Clinical and research information on drug-induced liver injury, pemoline.
